Vir Biotechnology
A commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases.
Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its development pipeline consists of product candidates targeting hepatitis B and D viruses, influenza A, human immunodeficiency virus and COVID-19.
Latest Vir Biotechnology News & Features
6 June 2024
14 February 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze